Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory

Completed · Phase 4 · Has a placebo group

Conditions studied: Attention Deficit Hyperactivity Disorder

In brief

This study investigates whether OROS-methylphenidate improves performance on different aspects of attention and memory in children with Attention-Deficit Hyperactivity Disorder (ADHD).

Key facts

Study ID: NCT00530257
Run by: Children's Hospital of Philadelphia
People needed: 30
Starts: 2004-06-01
Expected to finish: 2008-06-01
Last updated by the study team: 2011-12-19

Who can join

Age: 6 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Meets Diagnostic and Statistical Manual-IV Edition (DSM-IV) Criteria for ADHD.Combined Type
Parent and Teacher Ratings >85 percentile on inattention and/or hyperactivity/impulsivity scales
Estimated Intelligence Quotient (IQ) > 80 on Wechsler Abbreviated Scale of Intelligence or similar IQ test

You may not qualify if…

Past or current diagnosis of Tourette syndrome or chronic tic disorder, Pervasive Developmental Disorder (PDD), Cerebral Palsy, Head Injury requiring hospitalization, psychotic disorder, hypertension, glaucoma, cardiovascular disease, severe narrowing of the gastrointestinal tract, or epilepsy
Current diagnosis of bipolar disorder, obsessive-compulsive disorder serious enough to warrant separate treatment, suicidal or homicidal behavior or ideation
Use within 14-days of a monoamine oxidase inhibitor
History of side effects on any methylphenidate preparation that required stopping the medication
Inability to swallow a capsule or tablet
Chronic treatment with coumarin, clonidine, or tricyclic antidepressants

Where it is running

The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.